> Detailanzeige

Wang, Lei [VerfasserIn]; Jin, Nan [VerfasserIn]; Schmitt, Anita [VerfasserIn]; Malcherek, Georg [VerfasserIn]; Hundemer, Michael [VerfasserIn]; Mani, Jiju [VerfasserIn]; Hose, Dirk [VerfasserIn]; Raab, Marc-Steffen [VerfasserIn]; Ho, Anthony Dick [VerfasserIn]; Goldschmidt, Hartmut [VerfasserIn]; Schmitt, Michael [VerfasserIn]

T cell-based targeted immunotherapies for patients with multiple myeloma

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: T cell-based targeted immunotherapies for patients with multiple myeloma
  • Beteiligte: Wang, Lei [VerfasserIn]; Jin, Nan [VerfasserIn]; Schmitt, Anita [VerfasserIn]; Malcherek, Georg [VerfasserIn]; Hundemer, Michael [VerfasserIn]; Mani, Jiju [VerfasserIn]; Hose, Dirk [VerfasserIn]; Raab, Marc-Steffen [VerfasserIn]; Ho, Anthony Dick [VerfasserIn]; Goldschmidt, Hartmut [VerfasserIn]; Schmitt, Michael [VerfasserIn]
  • Erschienen: 2015
  • Erschienen in: International journal of cancer ; 136(2015), 8, Seite 1751-1768
  • Sprache: Englisch
  • DOI: 10.1002/ijc.29190
  • ISSN: 1097-0215
  • Identifikator:
  • Schlagwörter: clinical trials ; genetic engineering ; immunotherapy ; multiple myeloma ; tumor antigens
  • Entstehung:
  • Anmerkungen: Online 8 September 2014
  • Beschreibung: Despite high-dose chemotherapy followed by autologs stem-cell transplantation as well as novel therapeutic agents, multiple myeloma (MM) remains incurable. Following the general trend towards personalized therapy, targeted immunotherapy as a new approach in the therapy of MM has emerged. Better progression-free survival and overall survival after tandem autologs/allogeneic stem cell transplantation suggest a graft versus myeloma effect strongly supporting the usefulness of immunological therapies for MM patients. How to induce a powerful antimyeloma effect is the key issue in this field. Pivotal is the definition of appropriate tumor antigen targets and effective methods for expansion of T cells with clinical activity. Besides a comprehensive list of tumor antigens for T cell-based approaches, eight promising antigens, CS1, Dickkopf-1, HM1.24, Human telomerase reverse transcriptase, MAGE-A3, New York Esophageal-1, Receptor of hyaluronic acid mediated motility and Wilms' tumor gene 1, are described in detail to provide a background for potential clinical use. Results from both closed and on-going clinical trials are summarized in this review. On the basis of the preclinical and clinical data, we elaborate on three encouraging therapeutic options, vaccine-enhanced donor lymphocyte infusion, chimeric antigen receptors-transfected T cells as well as vaccines with multiple antigen peptides, to pave the way towards clinically significant immune responses against MM.
  • Zugangsstatus: Freier Zugang